Multi-Omics Analysis Identifying Key Biomarkers in Ovarian Cancer

• Published in: Cancer control Vol. 27; no. 1; p. 1073274820976671
• Main Authors: Li, Ju-Yueh, Li, Chia-Jung, Lin, Li-Te, Tsui, Kuan-Hao
• Format: Journal Article
• Language: English
• Published: Los Angeles, CA SAGE Publications 01-10-2020; Sage Publications Ltd; SAGE Publishing
• Subjects: AKT1 protein; Bioinformatics; Copy number; Cyclic AMP response element-binding protein; Gene therapy; Medical prognosis; Molecular Basis of Carcinogenesis; Ovarian cancer; p53 Protein; Prognosis; Protein interaction; Proteins; Tumors; ovarian cancer; prognosis; biomarkers; bioinformatics
• ISSN: 1073-2748; 1526-2359; 1073-2748
• DOI: 10.1177/1073274820976671

Ovarian cancer is one of the most common malignant tumors. Here, we aimed to study the expression and function of the CREB1 gene in ovarian cancer via the bioinformatic analyses of multiple databases. Previously, the prognosis of ovarian cancer was based on single-factor or single-gene studies. In this study, different bioinformatics tools (such as TCGA, GEPIA, UALCAN, MEXPRESS, and Metascape) have been used to assess the expression and prognostic value of the CREB1 gene. We used the Reactome and cBioPortal databases to identify and analyze CREB1 mutations, copy number changes, expression changes, and protein–protein interactions. By analyzing data on the CREB1 differential expression in ovarian cancer tissues and normal tissues from 12 studies collected from the “Human Protein Atlas” database, we found a significantly higher expression of CREB1 in normal ovarian tissues. Using this database, we collected information on the expression of 25 different CREB-related proteins, including TP53, AKT1, and AKT3. The enrichment of these factors depended on tumor metabolism, invasion, proliferation, and survival. Individualized tumors based on gene therapy related to prognosis have become a new possibility. In summary, we established a new type of prognostic gene profile for ovarian cancer using the tools of bioinformatics.